

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock code: 8037)**

### SUPPLEMENTAL ANNOUNCEMENT FURTHER INFORMATION IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Reference is made to the annual report of China Biotech Services Holdings Limited (the “**Company**”) for the year ended 31 December 2022 published on 29 March 2023 (the “**Annual Report**”). Unless otherwise stated, capitalised terms used herein shall have the same meanings as defined in the Annual Report.

In additional to the information disclosed in the Annual Report, the Company would like to provide the following information:

**Under the table on page 18 (revisions are shown in underline):**

Intended use	Net proceeds <i>HK\$'000</i>	Utilisation up to 31 December 2022 <i>HK\$'000</i>	Remaining balance as at 31 December 2022 <i>HK\$'000</i>	<u>Intended use and expected timeline of the remaining amount of net proceeds</u>
Investment in BNCT project	23,340 (equivalent to approximately US\$3.000 million)	Nil	23,340 (equivalent to approximately US\$3.000 million)	<u>The remaining unutilised amount of HK\$23,340,000 will be used for investment in BNCT project and is expected to be fully utilised by 30 September 2023.</u>

Intended use	Net proceeds HK\$'000	Utilisation up to 31 December 2022 HK\$'000	Remaining balance as at 31 December 2022 HK\$'000	<u>Intended use and expected timeline of the remaining amount of net proceeds</u>
Research and development costs and general working capital	15,124 (equivalent to approximately US\$1.944 million)	Nil	15,124 (equivalent to approximately US\$1.944 million)	<u>The remaining unutilised amount of HK\$15,124,000 will be used for research and development costs and general working capital and is expected to be fully utilised by 30 September 2023.</u>

As at the date of this announcement, the net proceeds were used, or are proposed to be used, according to the intentions previously disclosed by the Company in its announcement dated 20 December 2022 and the Annual Report and the Directors are not aware of any material change to the intended use of the net proceeds set forth above.

Save as disclosed above, all other information set out in the Annual Report remains unchanged.

By order of the Board  
**China Biotech Services Holdings Limited**  
**Liu Xiaolin**  
*Chairman and Executive Director*

Hong Kong, 9 August 2023

*As at the date of this announcement, the Board of Directors comprises three executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun and Mr. Huang Song; one non-executive Director, namely Ms. Chui Hoi Yam; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of the Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the "Latest Listed Company Information" page of the website of The Stock Exchange of Hong Kong Limited at [www.hkexnews.hk](http://www.hkexnews.hk) for at least 7 days from the date of its publication and on the website of the Company at [www.cbshhk.com](http://www.cbshhk.com).*